Clinical Observation of Raltitrexed Plus Cisplatin Through Hyperthermic Intraperitoneal Chemoperfusion in the Treatment of Malignant Ascites
Author(s): HU Xiaoyan, DU Fangmin, DONG Xiaofang, XU Li
Pages: 114-117
Year: 2017 Issue: 2
Journal: Journal of Basic and Clinical Oncology
Keyword: intraperitoneal hyperthermic chemoperfusion; raltitrexed; cisplatin; malignant ascites;
Abstract: Objective To investigate the effects of raltitrexed plus cisplatin through intraperitoneal hyperthermic chemoperfusion in the treatment of malignant ascites.Methods The 40 patients with malignant ascites were randomly divided into the treatment group and the control group.In the treatment group,the 20 patients were treated with raltitrexed 4 mg and cisplatin 60 mg·m-2 by intraperitoneal hyperthermic chemoperfusion about two to four cycles every three weeks.In the control group,the 20 patients were just treated with cisplatin 60 mg·m-2 by intraperitoneal hyperthermic chemoperfusion.The therapeutic effects of the two groups was compared.The related complication and adverse reaction were recorded.Results The effective rate in the treatment group was 85.0%,and was significantly higher than that in the control group (65.0%,P<0.05).The KPS scores in the treatment group were higher than those in the control group,but there was no statistical difference (P>0.05).No raltitrexed related complication and adverse reaction were observed in the treatment group.Conclusion Raltitrexed plus cisplatin through intraperitoneal hyperthermic chemoperfusion is better than cisplatin through intraperitoneal hyperthermic chemoperfusion,and the related adveres reaction is not increased.So it is one kind of safe and high-efficient therapy instrument to malignant ascites.
Pages: 114-117
Year: 2017 Issue: 2
Journal: Journal of Basic and Clinical Oncology
Keyword: intraperitoneal hyperthermic chemoperfusion; raltitrexed; cisplatin; malignant ascites;
Abstract: Objective To investigate the effects of raltitrexed plus cisplatin through intraperitoneal hyperthermic chemoperfusion in the treatment of malignant ascites.Methods The 40 patients with malignant ascites were randomly divided into the treatment group and the control group.In the treatment group,the 20 patients were treated with raltitrexed 4 mg and cisplatin 60 mg·m-2 by intraperitoneal hyperthermic chemoperfusion about two to four cycles every three weeks.In the control group,the 20 patients were just treated with cisplatin 60 mg·m-2 by intraperitoneal hyperthermic chemoperfusion.The therapeutic effects of the two groups was compared.The related complication and adverse reaction were recorded.Results The effective rate in the treatment group was 85.0%,and was significantly higher than that in the control group (65.0%,P<0.05).The KPS scores in the treatment group were higher than those in the control group,but there was no statistical difference (P>0.05).No raltitrexed related complication and adverse reaction were observed in the treatment group.Conclusion Raltitrexed plus cisplatin through intraperitoneal hyperthermic chemoperfusion is better than cisplatin through intraperitoneal hyperthermic chemoperfusion,and the related adveres reaction is not increased.So it is one kind of safe and high-efficient therapy instrument to malignant ascites.
Related Articles